Citi Upgrades Merus N.V. (MRUS) to Buy
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/10/2026
- Wall St flat as SK Hynix's stellar debut limits losses in chip stocks
- Oil prices fall on hopes for smoother shipping in Strait of Hormuz
- The real reason Meta shares are surging has nothing to do with its new AI model
- Stifel lifts Shopify to Buy, sees agentic commerce as next growth catalyst
- Delta Air Lines stock climbs on earnings beat and strong guidance
- Key things to know ahead of SK Hynix’s blockbuster US listing
- Almonty Industries (ALM) PT Raised to $33 at DA Davidson
- Meta falls as massive AI infrastructure spending plans overshadow chip progress
- S&P Downgrades Oracle To 'bbb-/A-3'; Outlook Stable
- The real reason Meta shares are surging has nothing to do with its new AI model
Incyte and Merus Announce Global Strategic Research Collaboration to Discover and Develop Bispecific Antibodies
December 21, 2016 7:00 AM ESTCollaboration designed to leverage Merus Biclonics® bispecific antibody technology to expand Incytes discovery capabilities and large-molecule portfolio Incyte to make up-front payment of $120 million and purchase $80 million of Merus common shares; Merus eligible to receive potential development, regulatory and commercial milestones and sales royalties Merus conference call scheduled today at 8:30 a.m. ET, 2:30 p.m. CET
WILMINGTON, Del. & UTRECHT, Netherlands--(BUSINESS WIRE)-- Incyte Corporation (NASDAQ: INCY) and Merus N.V. (NASDAQ: MRUS) announced... More
